| Date | Panel | Item | Activity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Haematological malignancies cancer susceptibility v2.15 | CSF3R | Arina Puzriakova Classified gene: CSF3R as Red List (low evidence) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Haematological malignancies cancer susceptibility v2.15 | CSF3R | Arina Puzriakova Added comment: Comment on list classification: New gene added by Kiran Tawana (Addenbrooke's Hospital, Cambridge). Rating Red as increased risk of AML due to CSF3R is associated with acquired rather than hereditary variants. One individual from PMID: 19620628 did develop a myelodysplastic syndrome, however this is not sufficient to promote this gene at present. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Haematological malignancies cancer susceptibility v2.15 | CSF3R | Arina Puzriakova Gene: csf3r has been classified as Red List (Low Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Haematological malignancies cancer susceptibility v2.14 | CSF3R | Arina Puzriakova Phenotypes for gene: CSF3R were changed from MDS; Myeloma; B-ALL to Acute myeloid leukaemia; Hereditary neutrophilia; Neutropenia, severe congenital, 7, autosomal recessive, OMIM:617014 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Haematological malignancies cancer susceptibility v2.13 | CSF3R | Arina Puzriakova Publications for gene: CSF3R were set to PMID: 27939403 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Haematological malignancies cancer susceptibility v2.12 | CSF3R | Arina Puzriakova Tag somatic tag was added to gene: CSF3R. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Haematological malignancies cancer susceptibility v2.12 | CSF3R | Arina Puzriakova reviewed gene: CSF3R: Rating: ; Mode of pathogenicity: None; Publications: 19620628, 12203110, 24753537, 26324699; Phenotypes: Acute myeloid leukaemia, Hereditary neutrophilia, Neutropenia, severe congenital, 7, autosomal recessive, OMIM:617014; Mode of inheritance: MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Haematological malignancies cancer susceptibility v2.5 | CSF3R | Kiran Tawana reviewed gene: CSF3R: Rating: AMBER; Mode of pathogenicity: None; Publications: PMID: 27939403; Phenotypes: MDS, Myeloma, B-ALL; Mode of inheritance: MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Haematological malignancies cancer susceptibility v2.5 | CSF3R | Kiran Tawana Deleted their review | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Haematological malignancies cancer susceptibility v2.5 | CSF3R |
Kiran Tawana gene: CSF3R was added gene: CSF3R was added to Haematological malignancies cancer susceptibility. Sources: Literature Mode of inheritance for gene: CSF3R was set to MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown Publications for gene: CSF3R were set to PMID: 27939403 Phenotypes for gene: CSF3R were set to MDS; Myeloma; B-ALL Penetrance for gene: CSF3R were set to unknown Review for gene: CSF3R was set to RED Added comment: Sources: Literature |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||